Lessons from the 'Iressa' Expanded Access Programme: Gefitinib in special non-small-cell lung cancer patient populations

R. Stahel, A. Rossi, L. Petruzelka, P. Kosimidis, F. De Braud, M. M. Bernardo, P. J. Souquet, H. Soto Parra, C. Gridelli

Research output: Contribution to journalArticle

Abstract

Some subgroups of patients with advanced/metastatic non-small-cell lung cancer (NSCLC) are frequently considered ineligible for the aggressive, platinum-based combination chemotherapy that is the recommended treatment. Elderly patients may have a poorer tolerance of chemotherapy due to impaired organ function and frequent comorbidities; patients with poor performance status (PS; ≥ 2 due to NSCLC and/or coexisting illnesses) are often considered unfit for chemotherapy; other patients may be unable or unwilling to endure the toxicity or inconvenience of chemotherapy. These patient groups may benefit from novel, relatively nontoxic treatment modalities. Gefitinib ('Iressa', ZD1839) 250 mg day-1 is well tolerated and has proven antitumour and symptom improvement activity in patients with previously treated NSCLC. Phase II trials (IDEAL 1 and 2) of gefitinib in advanced/metastatic NSCLC included 70 out of 425 (16.5%) patients with PS ≥ 2, and their response rate, clinical benefit rate and rates of adverse events were similar to those of the overall trial population. In addition, many patients with advanced/metastatic NSCLC with poor PS or advanced age have received gefitinib 250 mg day-1 in an Expanded Access Programme (EAP). Observations from the EAP support those of IDEAL 1 and 2, and indicate that gefitinib 250 mg day-1 warrants further investigation in these patient groups.

Original languageEnglish
JournalBritish Journal of Cancer
Volume89
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Population
Drug Therapy
gefitinib
Combination Drug Therapy
Platinum
Comorbidity
Therapeutics

Keywords

  • Chemonaive
  • EGFR-TKI
  • Elderly
  • Gefitinib ('Iressa', ZD1839)
  • NSCLC
  • Performance status

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lessons from the 'Iressa' Expanded Access Programme : Gefitinib in special non-small-cell lung cancer patient populations. / Stahel, R.; Rossi, A.; Petruzelka, L.; Kosimidis, P.; De Braud, F.; Bernardo, M. M.; Souquet, P. J.; Soto Parra, H.; Gridelli, C.

In: British Journal of Cancer, Vol. 89, No. SUPPL. 2, 12.2003.

Research output: Contribution to journalArticle

Stahel, R, Rossi, A, Petruzelka, L, Kosimidis, P, De Braud, F, Bernardo, MM, Souquet, PJ, Soto Parra, H & Gridelli, C 2003, 'Lessons from the 'Iressa' Expanded Access Programme: Gefitinib in special non-small-cell lung cancer patient populations', British Journal of Cancer, vol. 89, no. SUPPL. 2. https://doi.org/10.1038/sj.bjc.6601479
Stahel, R. ; Rossi, A. ; Petruzelka, L. ; Kosimidis, P. ; De Braud, F. ; Bernardo, M. M. ; Souquet, P. J. ; Soto Parra, H. ; Gridelli, C. / Lessons from the 'Iressa' Expanded Access Programme : Gefitinib in special non-small-cell lung cancer patient populations. In: British Journal of Cancer. 2003 ; Vol. 89, No. SUPPL. 2.
@article{af24a6a1a9244480840193e3f74330d9,
title = "Lessons from the 'Iressa' Expanded Access Programme: Gefitinib in special non-small-cell lung cancer patient populations",
abstract = "Some subgroups of patients with advanced/metastatic non-small-cell lung cancer (NSCLC) are frequently considered ineligible for the aggressive, platinum-based combination chemotherapy that is the recommended treatment. Elderly patients may have a poorer tolerance of chemotherapy due to impaired organ function and frequent comorbidities; patients with poor performance status (PS; ≥ 2 due to NSCLC and/or coexisting illnesses) are often considered unfit for chemotherapy; other patients may be unable or unwilling to endure the toxicity or inconvenience of chemotherapy. These patient groups may benefit from novel, relatively nontoxic treatment modalities. Gefitinib ('Iressa', ZD1839) 250 mg day-1 is well tolerated and has proven antitumour and symptom improvement activity in patients with previously treated NSCLC. Phase II trials (IDEAL 1 and 2) of gefitinib in advanced/metastatic NSCLC included 70 out of 425 (16.5{\%}) patients with PS ≥ 2, and their response rate, clinical benefit rate and rates of adverse events were similar to those of the overall trial population. In addition, many patients with advanced/metastatic NSCLC with poor PS or advanced age have received gefitinib 250 mg day-1 in an Expanded Access Programme (EAP). Observations from the EAP support those of IDEAL 1 and 2, and indicate that gefitinib 250 mg day-1 warrants further investigation in these patient groups.",
keywords = "Chemonaive, EGFR-TKI, Elderly, Gefitinib ('Iressa', ZD1839), NSCLC, Performance status",
author = "R. Stahel and A. Rossi and L. Petruzelka and P. Kosimidis and {De Braud}, F. and Bernardo, {M. M.} and Souquet, {P. J.} and {Soto Parra}, H. and C. Gridelli",
year = "2003",
month = "12",
doi = "10.1038/sj.bjc.6601479",
language = "English",
volume = "89",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Lessons from the 'Iressa' Expanded Access Programme

T2 - Gefitinib in special non-small-cell lung cancer patient populations

AU - Stahel, R.

AU - Rossi, A.

AU - Petruzelka, L.

AU - Kosimidis, P.

AU - De Braud, F.

AU - Bernardo, M. M.

AU - Souquet, P. J.

AU - Soto Parra, H.

AU - Gridelli, C.

PY - 2003/12

Y1 - 2003/12

N2 - Some subgroups of patients with advanced/metastatic non-small-cell lung cancer (NSCLC) are frequently considered ineligible for the aggressive, platinum-based combination chemotherapy that is the recommended treatment. Elderly patients may have a poorer tolerance of chemotherapy due to impaired organ function and frequent comorbidities; patients with poor performance status (PS; ≥ 2 due to NSCLC and/or coexisting illnesses) are often considered unfit for chemotherapy; other patients may be unable or unwilling to endure the toxicity or inconvenience of chemotherapy. These patient groups may benefit from novel, relatively nontoxic treatment modalities. Gefitinib ('Iressa', ZD1839) 250 mg day-1 is well tolerated and has proven antitumour and symptom improvement activity in patients with previously treated NSCLC. Phase II trials (IDEAL 1 and 2) of gefitinib in advanced/metastatic NSCLC included 70 out of 425 (16.5%) patients with PS ≥ 2, and their response rate, clinical benefit rate and rates of adverse events were similar to those of the overall trial population. In addition, many patients with advanced/metastatic NSCLC with poor PS or advanced age have received gefitinib 250 mg day-1 in an Expanded Access Programme (EAP). Observations from the EAP support those of IDEAL 1 and 2, and indicate that gefitinib 250 mg day-1 warrants further investigation in these patient groups.

AB - Some subgroups of patients with advanced/metastatic non-small-cell lung cancer (NSCLC) are frequently considered ineligible for the aggressive, platinum-based combination chemotherapy that is the recommended treatment. Elderly patients may have a poorer tolerance of chemotherapy due to impaired organ function and frequent comorbidities; patients with poor performance status (PS; ≥ 2 due to NSCLC and/or coexisting illnesses) are often considered unfit for chemotherapy; other patients may be unable or unwilling to endure the toxicity or inconvenience of chemotherapy. These patient groups may benefit from novel, relatively nontoxic treatment modalities. Gefitinib ('Iressa', ZD1839) 250 mg day-1 is well tolerated and has proven antitumour and symptom improvement activity in patients with previously treated NSCLC. Phase II trials (IDEAL 1 and 2) of gefitinib in advanced/metastatic NSCLC included 70 out of 425 (16.5%) patients with PS ≥ 2, and their response rate, clinical benefit rate and rates of adverse events were similar to those of the overall trial population. In addition, many patients with advanced/metastatic NSCLC with poor PS or advanced age have received gefitinib 250 mg day-1 in an Expanded Access Programme (EAP). Observations from the EAP support those of IDEAL 1 and 2, and indicate that gefitinib 250 mg day-1 warrants further investigation in these patient groups.

KW - Chemonaive

KW - EGFR-TKI

KW - Elderly

KW - Gefitinib ('Iressa', ZD1839)

KW - NSCLC

KW - Performance status

UR - http://www.scopus.com/inward/record.url?scp=0346057792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346057792&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601479

DO - 10.1038/sj.bjc.6601479

M3 - Article

C2 - 14661049

AN - SCOPUS:0346057792

VL - 89

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - SUPPL. 2

ER -